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Abstract: Human cathepsin L belongs to the cathepsin family of proteolytic enzymes with primarily
an endopeptidase activity. Although its primary functions were originally thought to be only of a
housekeeping enzyme that degraded intracellular and endocytosed proteins in lysosome, numerous
recent studies suggest that it plays many critical and specific roles in diverse cellular settings.
Not surprisingly, the dysregulated function of cathepsin L has manifested itself in several human
diseases, making it an attractive target for drug development. Unfortunately, several redundant and
isoform-specific functions have recently emerged, adding complexities to the drug discovery process.
To address this, a series of chemical biology tools have been developed that helped define cathepsin L
biology with exquisite precision in specific cellular contexts. This review elaborates on the recently
developed small molecule inhibitors and probes of human cathepsin L, outlining their mechanisms
of action, and describing their potential utilities in dissecting unknown function.
Keywords: human cathepsin L; cathepsin L probe; cathepsin L inhibitor; activity-based probes;
clickable ABP; E-64; CA-074; KDP-1; cathepsin L ABP
1. Introduction
Lysosomes play critical roles in human biology receiving, trafficking, processing, and degrading
biological molecules from seminal cellular processes, such as endocytosis, phagocytosis, autophagy
and secretion. Discovered by the ground-breaking work of de Duve, these single-membrane enclosed
cytosolic organelle maintain an acidic (~4.5–5) pH environment, and house close to sixty proteolytic
enzymes [1,2]. Among these are the eleven members of the cysteine cathepsin enzymes with a
versatile expression and functional profile: Cathepsin L (L1), B, C, F, H, K, O, V (L2), X, S, and
W [3]. These enzymes closely mimic the CA1 clan of the papain structure and catalytic cycle and
mediate numerous crucial cellular events. For example, they participate in processes involving cell
death, protein degradation, post-translational modifications of proteins, extracellular matrix (ECM)
remodeling, autophagy, and immune signaling. Given that their functions are aberrantly dysregulated
in several human diseases, many are considered prime targets for therapeutic development [4]. Several
elegant reviews have recently emerged describing the importance of cysteine cathepsins in both normal
physiology and human diseases [5–11]. The focus of this review is specifically on human cathepsin L,
a ubiquitously expressed endopeptidase whose involvement in several human diseases has emerged
in recent years. These include liver fibrosis, Type I and II diabetes, cardiac and bone, immune and
kidney disorders [12–24] In addition, its role in a wide variety of highly invasive forms of cancer is
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also now well established and has been a subject of elegant reviews elsewhere [25–27]. Unfortunately,
several overlapping and redundant functions of cathepsin L have also emerged [5,28–30]. It is therefore
critically important that its functional biology in both normal and disease-specific cell types be clearly
annotated before significant resources are directed in drug discovery endeavors. In this review, we will
briefly outline the biogenesis of cathepsin L, describe its post-translational processing and trafficking,
and highlight key structural features required for formation of an active and mature cathepsin L. A brief
summary of cathepsin L biology and its role in human diseases is provided next. Finally, a detailed and
up-to-date report on existing cathepsin L-targeting small molecule inhibitors and functional probes
with their mechanistic details is described.
Human cathepsin L gene, CTHL (Uniprot primary accession number: P07711), located at
the 9q21-q22 position of chromosome 9, encodes for a total of 333 amino acid peptide sequence
(M.W. = 37,564 kDa) [31]. The coding space includes the regions of a N-terminal signal peptide,
two pro-peptides, and two mature peptides comprising of a heavy (H) chain and a light (L) chain
(Figure 1). After transcription, the signal peptide is co-translationally removed in polysome and
the resulting 41 kDa pro-cathepsin L is translocated to endoplasmic reticulum where it undergoes
N-linked glycosylation with mannose rich sugars. The mannose sugars on the pro-cathepsin L are then
phosphorylated in cis Golgi by UDP-N-acetylglucosamine:N-acetylglucosaminephosphotransferase
enzyme [32]. The mannose-6-phosphate (M6P) receptors located on the surface of the trans Golgi
network recognize the M6P-pro-cathepsin peptide and deliver the pro-cathepsin L peptide to the
lysosome via the endolysosomal pathway. The weakly acidic environment of endosome/lysosome
releases M6P receptors and the phosphate group from mannose sugars is removed by a lysosomal acid
phosphatase [33,34]. Activation to mature cathepsin L form then occurs by removal of propeptides
either by autocatalysis [35] or by aspartyl cathepsin D in the acidic environment of lysosome [36].
This leads to the double chain form of mature and active cathepsin L, comprising of H and L domains,
connected by disulfide bridges, (Figure 2). It is to be noted here that several isoforms of cathepsin
L have also been observed in specific cell types due to alternative splicing of mRNA transcripts and
alternative translation [4,37–41].
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Figure 1. The primary sequence of the full length human inactive human cathepsin L: Blue = 17 Amino 
acid signal (prepro) peptide, Purple = Propeptides/activation peptides: 96 amino acid (Thr18–Glu113) 
and 3 amino acid (Glu289–Asp291), Red = Heavy chain peptide, Pink = Light chain peptide; * Disulfide 
bond pair residues, Cys135–Cys178, Ɵ Disulfide bond pair Cys169–Cys211, Ω Disulfide bond pair 
Cys268–Cys322, ¥ The site of N-linked glycosylation. The two key catalytic residues of the active site, 
Cys25 and His163 (numbering of mature cathepsin L) residing in the heavy chain are underlined. 
The propeptides act as an important regulatory on/off switch as well as a folding catalyst in 
cathepsin activation. Not surprisingly, the nature of propeptides among cysteine cathepsins is highly 
divergent by both chain lengths and primary sequences. It is thought that this uniqueness is 
functionally relevant given its ubiquitous presence in most tissues and allows for the selective 
suppression of enzyme activity (hence unintended autoactivation) during the transport to the 
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he ro e ti es act as an i ortant reg latory on/off s itch as ell as a fol ing catalyst in
cathe sin activation. ot surprisingly, the nat re of ro e ti es a ong cysteine cathe sins is highly
ivergent by both chain lengths and primary sequences. It is thought that this uniqueness is functionally
relevant given its ubiquitous presence in most tissues and allows for the selective suppression of enzyme
activity (hence unintended autoactivation) during the transport to the endolysosomal compartment.
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In cathepsin L, two inhibitory propeptides, one containing 96 amino acid (Thr18–Glu113) and the
other containing 3 amino acid (Glu289–Asp291) exist. A crystal structure of human procathepsin L
revealed that the 96 amino acid inhibitory propeptide chain spans in the opposite directions of substrate
binding and forms several high-affinity non-covalent interactions with the surrounding residues in
active site [42,43]. Interestingly, this opposite direction binding of inhibitory propeptide segment is
evolutionarily conserved in other members of cysteine cathepsins, including in cathepsin B.
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Figure 2. Biogenesis of hu an cathepsin L. After the full length cathepsin L mRNA is transcribed,
it is translated in ribosomes. Following this, the full-length peptide enters the ribosomes-bound
endoplasmic reticulum lumen where signal peptide is removed. Pro-cathepsin L then enters the Golgi
network where it undergoes N-linked glycosylation at Asn108, followed by mannose phosphorylation
and formation of appropriate disulfide linkages. In the last step, modified procathepsin L is shuttled to
lysosome by endolysosomal pathways, generating the double chain form of active and mature human
cathepsin L.
The dominant path ay of regulation of activated and ature cathepsin L is by endogenous
protein inhibitors, cystatins, that like propeptide compete with the physiological substrates for binding
to the enzyme active site (Table 1) [5,44]. Interestingly, protein inhibitory agents of cathepsin L have
also been reported in other organisms. For example, Kotsyfakis M. et al. reported the existence of
two cathepsin L inhibitory proteins in the carrier of the main vector of Lyme disease-carrying parasite,
Ixodus scapularis. Named so because of its abilities to specifically inhibit cathepsin L (IC50 = 4.68 nM; Ki
= 95 pM) activity, sialostatin L abrogates the protective proteolytic activity of host cells at the infestation
sites, thereby promoting the tick’s survival [45]. In addition, it also possess a potent anti-inflammatory
and immunosuppressive activity by inhibiting cytotoxic killer T cells [46].
Table 1. Reported physiological inhibitory ligands of human cathepsin L with their inhibition constants.
Inhibitory Ligand Inhibition Constant (Ki)
Recombinant Cathepsin L Propeptide 0.088 nM [47] (p = 5.5)
Cysta in A 1.3 nM [48,49]
Cystatin B 0.23 nM [48,49]
Cystatin C <0.005 nM [50]
Cystatin D 18 nM [51]
P41 of MHC Class II Molecule 2 pM [52]
L-Kinenogen 1.7 pM [53,54]
Cystatin F 0.31 nM [55]
Sialostatin L 95 pM [45]
Antimicrobial Peptide LL-37 150 nM [56]
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2. Functional Biology of Cathepsin L and Its Role in Human Diseases
Different forms of cathepsin L enzyme have been isolated in distinct cell types and their intracellular
and extracellular environment [4]. At specific cellular locations, they seem to play pivotal roles in a wide
range of functional activities. In addition to the degradation of cellular proteins by the endolysosomal
pathway, cathepsin L also participates in the autophagic degradation pathway; it specifically degrades
two autophagosomal markers, LC3-II and GABARAP-II [57]. The specialized podocyte cells in the
kidney play a critical role in the retention of various proteins required to be maintained in blood
plasma [58]. It was shown that the cytoplasmic variant of active cathepsin L can degrade two key
proteins, GTPase dynamin and synaptopodin, required for podocyte’s proper glomerular filtration
function [23,59,60]. Consistently, a higher podocyte cathepsin L expression was found in a variety
of proteinuric kidney diseases, and its functional inhibition (e.g., by creating cathepsin L resistant
dynamin) led to reversing of the symptoms [23,61]. Interestingly, a nuclear isoform of cathepsin L is
associated with another unique function in kidney cells; it is involved in the proteolytic processing
of Cux1, a cell cycle regulatory transcription factor that promotes cell proliferation and polycystic
kidney disease (PKD) [62,63]. Indeed, in mouse model of PKD, a lower level of nuclear cathepsin L
was corelated with an increased level of Cux1 protein in cysts [62].
Another type of cells where cathepsin L seems to play a major role in maintaining homeostasis is
cardiomyocytes [17,64–67]. Early investigation by Stypmann et al. on a year old Ctsl−/−mice showed
that they developed many key traits of dilated cardiomyopathy, such as interstitial myocardial fibrosis,
cardiac chamber dilation, and impaired contraction. In addition, the newborn Ctsl−/−mice acquired
increased number of acidic organelles, although with altered morphology and function. These studies
indicate that the inhibition of cathepsin L activity in these cells is detrimental to the proper functioning
of cardiac cells. This was further corroborated by an overexpression study of cathepsin L in mice
cardiomyocytes that exhibited cardioprotective effect by inhibiting the Akt signaling pathway [68].
The function of secreted extracellular cathepsin L in cardiac remodeling and repair has also been studied
extensively since it is known that many proteins of extracellular matrix (ECM) are also the physiological
substrate of cathepsin L; these include laminin, collagen type I, IV and XVIII, and fibronectin [69–71].
Ischemic heart disease is major risk factor for diabetic patients, unable to maintain their sugar levels
efficiently. During cardiac repair, endothelial progenitor cells containing elevated levels of cathepsin L
home on ischemic cells, and initiate the process of neovascularization [72–74]. In uncontrolled diabetic
condition however, cathepsin L function in ECM space during neovascularization is significantly
impaired; this hampers the ischemic repair process [15,75].
Controlled release of trypsinogen from pancreatic acinar cells and its subsequent activation in
duodenum is a critically important event and must be tightly regulated. Dysregulated release of
activated trypsin results in an acute pancreatitis condition. While cathepsin B efficiently cleaves
trypsinogen to produce enhanced levels of active trypsin promoting pancreatitis, cathepsin L acts
a regulatory brake, and keeps the activation process under control. And it does so by cleaving
trypsinogen at a distinct site, 3 amino acids C terminal to cathepsin B, thereby inactivating trypsinogen
itself [76]. Consistently, Ctsl−/−mice showed increased trypsin activity in pancreas and surprisingly
reduced pancreatitis due to diminished inflammation; this effect was attributed due to enhanced
apoptosis of acinar cells (vs necrosis).
In neuro- and immuno-biology, cathepsin L has important documented roles as well [77–80].
For example, regulated secretory vesicles of the neuroendocrine system, such as chromaffin granules,
house many mature function-ready enkephalin opioid peptides. Upon appropriate signaling stimuli,
the activated enkephalin neuropeptides are secreted and released imparting their analgesic and
immune-cell specific functions. Studies by Yasothornsrikul et al. revealed that cathepsin L is the
proteolytic processing enzyme that renders active metenkephalin from proenkephalin [81]. In another
studies, the severity of symptoms due to antigen-induced arthritis (AAI) was significantly reduced in
Ctsl−/−mice due to a weakened T helper cell population in thymus [82].
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The expression of cathepsin L is highly dysregulated in several human diseases, including diabetes,
AAI, abdominal aortic aneurysm, liver fibrosis, and cancers [13,82–85]. Its involvement in numerous
forms of highly invasive cancers is particularly noteworthy and is covered in great detail in recent
reviews [25,26,86–88]. Early studies by Gottesman revealed that extracellular cathepsin L levels can
increase up to 200-fold in transformed cells [89]. In the ECM environment, they can rapidly degrade
several structural components and significantly increase the migratory/invasive potential of these cells,
promoting metastasis [86,87]. Not surprisingly, cathepsin L inhibition by small molecule is considered
a viable strategy for the development of novel anti-cancer agents.
3. Small Molecule Inhibitors
Over the years, several classes of physiological and synthetic inhibitors have been discovered
targeting cathepsin L. Herein, the focus is on non-physiological inhibitors that could broadly be
classified as reversible and irreversible inhibitors. Reversible and irreversible inhibitor could be
distinguished by means of the mechanistic approaches they utilize for enzyme inactivation. Reversible
inhibitors ‘generally’ engage with the target protein using non-covalent interaction; however, in certain
cases, they form a quasi-covalent bond which eventually disengages from the active site, say, upon
dilution. Irreversible inhibitors, on the other hand, permanently modify the protein of interest via
the formation of a stable covalent bond. While both reversible and irreversible inhibitors have their
pros and cons, it is generally believed that reversible inhibitors are preferred candidates in drug
discovery and irreversible inhibitors not so due to their adverse immune responses [90]. There are,
however, several examples of successful drugs being used in clinics that work by an irreversible
inhibitory mechanism [91]. Irreversible inhibitors are also widely utilized in functional biology (e.g.,
in the development of activity-based probes). The majority of synthetic cathepsin L inhibitors have
recognizable peptide sequences, often derived from its physiological substrates, that bind to the active
site of the protein and often contain strategically placed electrophilic warheads that trap the nucleophilic
Cys25 residue (Figure 3) for activity. Knowledge of enzyme structure and its associated substrate
specificity thus has played an important role in designing selective inhibitors of cathepsins [92,93].
In a seminal study, Choe et al. studied substrate specificity using a highly diversified positional
scanning synthetic combinatorial library comprised of 160,000 fluorogenic tetrapeptides; this allowed to
differentiate individual enzymes′ binding propensity based on their distinct amino acid preferences [93].
By capitalizing on this strategy, they successfully developed a selective substrate and substrate-based
inhibitor of cathepsin K. The other important contribution to our understanding of subsite binding
preferences of cathepsin L enzyme stems from several timely crystal structure studies that helped reveal
key difference in the structural landscape of enzyme subsites [94–96]. In an important study, Shenoy et
al. solved the crystal structure of ligand bound cathepsin L and documented the structural compositions
of ligand binding sites (Figure 4) [96]. Their analysis of Z-Phe-Tyr (O-tert-Butyl)-C(O)C(H)O bound
cathepsin L revealed that (a) S1 subsite is relatively wide and unrestricted and composed of Asp162,
Ser24, and Cys25, (b) S1′ subsite is guided by Leu144, Trp189, Ala138 and Gly139 where Trp189
associates with Trp193 and Phe143 and forms an aromatic cluster that accommodates the tert-butyl
group (c) side chains of Leu69 and Met70 help form the S2 subsite that engages in non-polar interactions
with the phenyl side chain, and finally, (d) the carboxybenzyl group finds interaction with the Gly68
residue of S3 subsite (Figure 4). However, it turns out that different ligands may find slightly altered
binding interactions with the enzyme subsites, depending on their structural features. For example,
Shenoy et al. showed that although Z-Phe-Tyr (O-tert-Butyl)-DMK binds to the same subsites of
cathepsin L as observed for the Z-Phe-Tyr (O-tert-Butyl)-C(O)C(H)O ligand and finds some alternative
interactions with residues from the active site pocket. This finding has been corroborated by other
studies as well that suggest that structural features of ligands can influence the subsite composition of
the cathepsin L enzyme [94,95,97,98]. Such information has been duly capitalized to develop different
classes of inhibitors that are discussed next. In the following section, we discuss the types of cathepsin
L-targeting chemotypes that have been utilized for development of small molecule inhibitors.
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3.1. Epoxysuccinates
Epoxysuccinate inhibitors have historically play a crucial role in deciphering the
cysteine protea e biology. Th s cla s of compoun s contai s an epoxide ring as an
elect ophi ic warhead that traps the active site catalyt c cysteine residu of the protein. E-64
(L-trans-Epoxysuccinyl-le cylamido(4-guanidino)butan ) (Entry 1; Table 2), perha s th most studied
commercially available universal cathepsin inhibitor of this class, showed only a marginal selectivity
towards cathepsin L compared to cathepsin B and a moderate 24-fold selectivity over cathepsin H,
as reported by Barrett et al. [99]. Although they developed several synthetic analogs of E-64 with
improved potency, they lacked desirable selectivity toward cathepsin L. They proposed the probable
binding orientation of E-64 that follows a non-substrate-like orientation, i.e., it occupies only non-prime
sites (Figure 3) at the enzyme pocket.
In another study, Gour-Salin et al. reported a number of epoxysuccinyl amino acid benzyl esters
in which they systematically varied the amino acid attached to the epoxide ring. This was intended to
investigate its effect in determining selectivity toward cathepsin L or S [100]. Their results surprisingly
indicate that the specificity of these analogs did not follow the trend, generally observed for substrate,
possibly due to E-64 like binding orientation at the enzyme pocket. Among all synthesized compounds,
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HO-Eps-Arg-OBzl (Entry 2, Table 2) showed a significant 89-fold selectivity for cathepsin L over
cathepsin S.
Notably in a seminal study, Katanuma et al. developed several cathepsin L-selective E-64 analogs
(Cathepsin L Inhibitor by Katunuma: CLIK) with the help of computational modeling based on the
stereo-structure [101]. Three of the developed CLIK inhibitors were hydrolytically stable and showed
highly selective inhibition for hepatic cathepsin L in vivo. Further, they elucidated the inhibition
mechanism of this class of compounds based on the crystal structure of papain-CLIK148 (Entry 3,
Table 2) complex [102]. This crystal structure revealed that CLIK148, unlike E-64, binds to both prime
and non-prime sites of the active site pocket. Notably, the specificity toward cathepsin L was attributed
to the existence of phenylalanine residue at the S2 site, and a hydrophobic interaction mediated by
N-terminal pyridine ring (Figure 3).
3.2. Peptidyldiazomethane and Peptidylchloromethane
The other classes of alkylating agents that initially played an important role in deciphering
the mechanistic aspects of cathepsin inhibition were peptidyldiazomethane (Entry 4, Table 2) and
peptidylchloromethane (Entry 5, Table 2). Crawford et al. reported highly potent inhibitors from these
two chemotypes that spans the active site and shows significant selectivity improvement over other
cysteine proteases [103]. However, these classes of inhibitors suffer from stability issues and have
found limited utility in in vivo assays.
3.3. Peptidylhydroxylamine and Peptidylhydroxamates
Peptidylhydroxylamines were first introduced as mechanism-based inhibitors of serine and
cysteine proteinases [104–107]. Bromme et al. adapted this scaffold and prepared a library of
N-peptidyl-O-acyl hydroxylamines which exhibited rapid and selective inactivation of several
lysosomal cysteine proteinases [108]. This class of inhibitors occupied the active site of the enzyme and
irreversibly inactivated cysteine cathepsins as the free enzyme activity was not recovered when the
enzyme-inhibitor complex was exposed to exhaustive ultrafiltration (up to an enzyme/free inhibitor ratio
of <1:0.05) or chromatography on Sephadex G-10. Among developed inhibitors, Z-Phe-Phe-NHO-MA
(Entry 6, Table 2) inhibited cathepsin L with most potency and showed significant selectivity, 58-fold
and 436-fold, over cathepsin S and cathepsin B, respectively. Interestingly the stability and efficacy
of this class of inhibitors were determined by the nature of substitutions on hydroxylamine oxygen
as their electron-withdrawing tendencies showed a positive correlation with inactivation kinetics.
Although this class of inhibitors exhibited desirable traits with respect to both potency and selectivity,
they suffered majorly from aqueous stability issue; half-lives (t1/2) only in the range of 45209 min
in aqueous solution. In another study, Bromme et al. developed a series of N-peptidyl-O-acyl
hydroxamates with lysine in P1 position with improved inhibitory profile for cysteine proteases over
their serine counterparts [109]. The maximum inhibition was observed by Z-Phe-Lys-NHO-NBz
(Entry 8, Table 2), with 7-fold selectivity over cathepsin S, and >100-fold selectivity over cathepsin B.
The authors postulated that the active site Cys residue attacks the carbonyl of the hydroxamate and
forms a tetrahedral intermediate, whereas the nitrogen of the hydroxamate, which primarily remains
deprotonated (pKa < 5), presumably engages in an electrostatic interaction with the active site His159
residue (Figure 5).
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the AOMK group drastically impacted the selectivity profiles of these inhibitors, suggesting the 
importance of the adjuvant effect of prime site targeting in determining the efficacy and selectivity of 
this class of compounds. This class of inhibitors found wide-spread utilities in detecting protease 











Shenoy et al., 2009
[128]
25




Cat L propeptide 
mimic 
IC50 (n ) 
19 
Cat K: 310 




al., 2002 [95] 





IC50 (n ) * 
1 
Cat V: 11 
Cat S: 14 
Cat B: 50 
Cat K: 137 
Reversible 
(In vitro) 




Oxocarbazate IC50 (n ) * 
0.4 




yers et al., 
2008 [130] 










yers et al., 
2008 [130] 
# Fractions ere not considered hile calculating selectivity factor; Inhibitory efficacy has been 
reported in hole nu bers only; a: Serine Proteases; II: Insignificant Inhibition; D: ot Deter ined; 
b Active for  of inhibitor is devoid of the phosphate group; * Preincubation for 4 h. 
3.4. Peptidyl Acyloxy ethanes/Acyloxy ethyl Ketones 
nother class of peptidyl inhibitors that spans the active site and utilizes the catalytic achinery 
of cathepsin L for effective attenuation of enzy e activity is peptidyl acyloxy ethanes. rantz et al. 
developed a library of inhibitory co pounds ith a general sequence, Z-Phe-X-C 2 C -R; here 
they syste atically varied the a ino acid residue at P1 (denoted as X) and P1′ (denoted as R) 
positions [112]. ong the synthesized co pounds, Z-Phe-Cys(SBn)-C 2 C -2,6-(CF3)2-Ph (Entry 
9, Table 2) exhibited al ost a diffusion-controlled inactivation kinetics to ard cathepsin L, ho ever 
it sho ed only arginal selectivity over cathepsin B and cathepsin S. By analyzing the structure-
activity relationships of the library, the author elucidated the i portance of S1′ site in cathepsin L 
that could potentially be used to harness selectivity a ong other cysteine cathepsins. In a separate 
study, Torkar et al. designed a library of peptides for cathepsin L that spanned the active site and 
attenuated the enzy e activity via a non-covalent interaction [113]. They initially evaluated the 
co pounds’ activities against cathepsin L and cathepsin B, and co pared their hits against cathepsin 
 and S. The authors discovered five ost selective non-covalent, peptidyl inhibitors of cathepsin L, 
and transfor ed the  into irreversible inhibitors by strategically appending electrophilic arhead 
(Figure 6) acyloxy ethyl ketone ( ) groups (Entry 10, Table 2). o ever, the attach ent of 
the  group drastically i pacted the selectivity profiles of these inhibitors, suggesting the 
i portance of the adjuvant effect of pri e site targeting in deter ining the efficacy and selectivity of 
this class of co pounds. This class of inhibitors found ide-spread utilities in detecting protease 
activity and ere utilized to develop activity-based probe; this ill be discussed in the later sections. 







Myers et al., 2008
[129–131]
26








Cat K: 310 




al., 2002 [95] 





IC50 (nM) * 
1 
Cat V: 11 
Cat S: 14 
Cat B: 50 
Cat K: 137 
Reversible 
(In vitro) 




Oxocarbazate IC50 (nM) * 
0.4 




Myers et al., 
2008 [130] 










Myers et al., 
2008 [130] 
# Fractions were not considered while calculating selectivity factor; Inhibitory efficacy has been 
reported in whole numbers only; a: Serine Proteases; II: Insignificant Inhibition; ND: Not Determined; 
b Active form of inhibitor is devoid of the phosphate group; * Preincubation for 4 h. 
3.4. Peptidyl Acyloxymethanes/Acyloxymethyl Ketones 
Another class of peptidyl inhibitors that spans the active site and utilizes the catalytic machinery 
of cathepsin L for effective attenuation of enzyme activity is peptidyl acyloxymethanes. Krantz et al. 
developed a library of inhibitory compounds with a general sequence, Z-Phe-X-CH2OCO-R; here 
they systematically varied the amino acid residue at P1 (denoted as X) and P1′ (denoted as R) 
positions [112]. Among the synthesized compounds, Z-Phe-Cys(SBn)-CH2OCO-2,6-(CF3)2-Ph (Entry 
9, Table 2) exhibited almost a diffusion-controlled inactivation kinetics toward cathepsin L, however 
it showed only marginal selectivity over cathepsin B and cathepsin S. By analyzing the structure-
activity relationships of the library, the author elucidated the importance of S1′ site in cathepsin L 
that could potentially be used to harness selectivity among other cysteine cathepsins. In a separate 
study, Torkar et al. designed a library of peptides for cathepsin L that spanned the active site and 
attenuated the enzyme activity via a non-covalent interaction [113]. They initially evaluated the 
compounds’ activities against cathepsin L and cathepsin B, and compared their hits against cathepsin 
K and S. The authors discovered five most selective non-covalent, peptidyl inhibitors of cathepsin L, 
and transformed them into irreversible inhibitors by strategically appending electrophilic warhead 
(Figure 6)—acyloxymethyl ketone (AOMK) groups (Entry 10, Table 2). However, the attachment of 
the AOMK group drastically impacted the selectivity profiles of these inhibitors, suggesting the 
importance of the adjuvant effect of prime site targeting in determining the efficacy and selectivity of 
this class of compounds. This class of inhibitors found wide-spread utilities in detecting protease 
activity and were utilized to develop activity-based probe; this will be discussed in the later sections. 
Oxoc rbazate IC50 (nM) *0.4 Cat B: 714
Reversible
(In vitro cellular)
Myers et al., 2008
[130]
Shah et al., 2010 [132]
27








Cat K: 310 




al., 2002 [95] 





IC50 (nM) * 
1 
Cat V: 11 
at S: 14 
Cat B: 50 
Cat K: 137 
Reversible 
(In vitro) 




Oxocarbazate IC50 (nM) * 
0.4 




Myers et al., 
2008 [130] 










Myers et al., 
2008 [130] 
# Fractions were not considered while calculating selectivity factor; Inhibitory efficacy has been 
reported in whole numbers only; a: Serine Proteases; II: Insignificant Inhibition; ND: Not Determined; 
b Active form of inhibitor is devoid of the phosphate group; * Preincubation for 4 h. 
3.4. Peptidyl Acyloxymethanes/Acyloxymethyl Ketones 
Another class of peptidyl inhibitors that spans the active site and utilizes the catalytic machinery 
of cathepsin L for effective attenuation of enzyme activity is peptidyl acyloxymethanes. Krantz et al. 
developed a library of inhibitory compounds with a general sequence, Z-Phe-X-CH2OCO-R; here 
they systematically varied the amino acid residue at P1 (denoted as X) and P1′ (denoted as R) 
positions [112]. Among the synthesized compounds, Z-Phe-Cys(SBn)-CH2OCO-2,6-(CF3)2-Ph (Entry 
9, Table 2) exhibited almost a diffusion-controlled inactivation kinetics toward cathepsin L, however 
it showed only marginal selectivity over cathepsin B and cathepsin S. By analyzing the structure-
activity relationships of the library, the author elucidated the importance of S1′ site in cathepsin L 
that could potentially be used to harness selectivity among other cysteine cathepsins. In a separate 
study, Torkar et al. designed a library of peptides for cathepsin L that spanned the active site and 
attenuated the enzyme activity via a non-covalent interaction [113]. They initially evaluated the 
compounds’ activities against cathepsin L and cathepsin B, and compared their hits against cathepsin 
K and S. The authors discovered five most selective non-covalent, peptidyl inhibitors of cathepsin L, 
and transformed them into irreversible inhibitors by strategically appending electrophilic warhead 
(Figure 6)—acyloxymethyl ketone (AOMK) groups (Entry 10, Table 2). However, the attachment of 
the AOMK group drastically impacted the selectivity profiles of these inhibitors, suggesting the 
importance of the adjuvant effect of prime site targeting in determining the efficacy and selectivity of 
this class of compounds. This class of inhibitors found wide-spread utilities in detecting protease 
activity and were utilized to develop activity-based probe; this will be discussed in the later sections. 
Aza-peptide IC50 (µM)3.0 ND
Reversible
(In vitro)
Myers et al., 2008
[130]
# Fractions were not considered while calculating selectivity factor; Inhibitory efficacy has been reported in whole numbers only; a: Serine Proteases; II: Insignificant Inhibition; ND: Not
Determined; b Active form of inhibitor is devoid of the phosphate group; * Preincubation for 4 h.
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nitrophenyl analog (Entry 7, Table 2) which incur both hydrophobicity and electron-withdrawing 
property exerted the maximum potency and selectivity for cathepsin L over other tested cysteine 
proteases. 
Table 2. Reported small molecule inhibitory agents of human cathepsin L, their mechanism of 
inhibition, inhibitory parameters and selectivity profile, and their demonstrated utilities. 

















Cat B: 1.1 
Cat H: 24 
Irreversible 
(In vitro) 





2nd Order (103 
M−1 s−1) 
73 








10−6 M (100% 
inhibition) 
Cat B: NI 
Cat S: 3 






Figure 5. Postulated active-site interactions bet een papain, a prototypical cysteine protease, and
peptidyl hydroxa ate inhibitor. Active-site cysteine forms a covalent bond with the carbonyl group of
the inhibitor and the negatively charged nitrogen engages in electrostatic interaction with the positively
charged histidine residue.
, r t l.
i i , i t i l f [ ].
l s of inhibitors covalently modified active-site Cys residue via sulfenamidation, like in
their N-peptidyl-O-acyl hydroxamate coun erparts, as shown by the mass sp ctrometric analysis.
These inhibitors further provid d the option of varying th leavin group tha targets S2′ site;
ic substi uents were preferred at this position as c mparis n of ki/Ki values of the inactivation
exhibited the following trend for Aa: Gly < Ala < Val < Leu < Phe 4-NO2-Ph. The nitrophenyl
analog (Entry 7, Table 2) which incur both hydrophobicity an electron-withdrawing property exerted
the maximum potency and selectivi y for cathepsin L over ther t sted cysteine proteases.
3.4. Peptidyl Acyloxymethanes/Acyloxymethyl Ketones
Another class of peptidyl inhibitors that spans the active site and utilizes the catalytic machinery
of cathepsin L for effective attenuation of enzyme activity is peptidyl acyloxymethanes. Krantz et al.
developed a library of inhibitory compounds with a general sequence, Z-Phe-X-CH2OCO-R; here
they systematically varied the amino acid residue at P1 (denoted as X) and P1′ (denoted as R)
positions [112]. Among the synthesized compounds, Z-Phe-Cys(SBn)-CH2OCO-2,6-(CF3)2-Ph (Entry 9,
Table 2) exhibited almost a diffusion-controlled inactivation kinetics toward cathepsin L, however it
showed only marginal selectivity over cathepsin B and cathepsin S. By analyzing the structure-activity
relationships of the library, the author elucidated the importance of S1′ site in cathepsin L that could
potentially be used to harness selectivity among other cysteine cathepsins. In a separate study, Torkar
et al. designed a library of peptides for cathepsin L that spanned the active site and attenuated the
enzyme activity via a non-covalent interaction [113]. They initially evaluated the compounds’ activities
against cathepsin L and cathepsin B, and compared their hits against cathepsin K and S. The authors
discovered five most selective non-covalent, peptidyl inhibitors of cathepsin L, and transformed them
into irreversible inhibitors by strategically appending electrophilic warhead (Figure 6)—acyloxymethyl
ketone (AOMK) groups (Entry 10, Table 2). However, the attachment of the AOMK group drastically
impacted the selectivity profiles of these inhibitors, suggesting the importance of the adjuvant effect of
prime site targeting in determining the efficacy and selectivity of this class of compounds. This class
of inhibitors found wide-spread utilities in detecting protease activity and were utilized to develop
activity-based probe; this will be discussed in the later sections.
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3.5. Peptidyl Aziridine
A very interesting class of inhibitors, the concept of which was derived from E-64, is peptidyl
aziridines. Martichonok et al. developed a series of aziridine derivatives of E-64 and tested them
against papain and cathepsin L and B [114]. Contrarily to E-64, in which (L)-diastereomer is more
potent than (D)-isomer, aziridine analogs exhibited the opposite trend while still inactivating the
enzymes. More importantly, the efficacy of this class of inhibitors was strongly pH-dependent
and showed maximal inhibitory potency at pH4; this is attributed to the protonated form of
aziridine ring that is more susceptible to nucleophilic attack by catalytic Cys residue. Among the
developed library, HO-(D)-Az-Leu-NH-iAm (Entry 11, Table 2) analog exhibited maximal inhibitory
potency towards cathepsin L with moderate selectivity over cathepsin B; the corresponding L isomer,
HO-(L)-Az-Leu-NH-iAm (Entry 11) was almost 10-fold less activity while maintaining the similar trend
in general. Since only protonated form of aziridine ring undergoes nucleophilic attack, presumably it
does not involve water molecule-mediated ring-opening like its epoxide counterpart E-64. Although
promising, a full potential of this class of compounds could presumably be achieved only below pH 4
when aziridine ring nitrogen gets completely protonated. This class of inhibitors thus lacks practical
utility as the catalytic cysteine of cathepsin L starts to lose its activity below pH 4 and the majority of the
cell-based assays are performed mostly at a pH higher than 4.0. In a notable study, Schirmeister et al.
developed three different classes of inhibitors with aziridine-2,3-dicarboxylic acid (Azi), an electrophilic
warhead, installed at different positions of the peptide chain (Figure 7) [115]. They performed a
thorough SAR analysis of this type of inhibitors, all off which exhibited time-dependent irreversible
inactivation of cathepsin L with no-recovery of enzyme activity, even after extensive dialysis of the
enzyme-inhibitor complex. Among type-I inhibitors, N-acylated aziridines with aziridine as C-terminal
amino acid, a mixture of diastereomeric peptides with procathepsin B sequence Leu-Gly-Gly (Entry 12,
Table 2), exhibited enhanced inhibition toward cathepsin L. This was attributed to an overall unique
folding of cathepsin L with a shallowness of the S2 pocket due to the presence of an additional Met161
residue. Type II class of inhibitors (Figure 7) resemble classic aziridine scaffold, N-unsubstituted
aziridines with aziridine as N-terminal amino acid, analogously to E-64 where nitrogen of aziridine
remained unsubstituted. Among the type II inhibitors tested, EtO-(R,R)-Azi-Leu-OBzl (Entry 13,
Table 2) inactivated cathepsin L with higher second-order rate constant than EtO-(S,S)-Azi-Leu-OBzl,
although the latter showed better selectivity over cathepsin B.
The type III inhibitor class (Figure 7) is comprised of N-acylated bispeptidyl derivatives of aziridine,
where aziridine ring rests in the middle of the peptide. BOC-Phe-(R,R)-(EtO)-Azi-Leu-Pro-OBzl (Entry
14, Table 2) of this series was 5-fold more potent than the (S,S) analog; however both exhibited only a
marginal selectivity over cathepsin B with diminished eudysmic ratio. The authors then superimposed
and analyzed the structures of certain epoxide and aziridines and postulated that these inhibitors
can assume different orientations in the active site while still binding within the enzyme pockets.
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This scaffold was further explored by Vicik et al. who extended the previous work and developed a
series of compounds in which Boc-(S)-Leu-(S)-Azy-(S,S)-Azi(OBn)2 (Figure 8), Type I analog, spanned
from S2 to S2′ pocket and inactivated cathepsin L with more than 700-fold selectivity over cathepsin
B [133]. This motif was also used for affinity labeling of cathepsin L, which will be discussed in the
later sections. These classes of compounds, especially N-unsubstituted aziridinyl peptides and in
special cases N-acylated ones, exhibited a high selectivity and potency and provided the premise for
the further development of chemical biology tools much needed for functional studies.Molecules 2020, 25, 698 13 of 40 
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Mendieta et al., the authors developed a structurally novel library of twenty peptidyl 3-aryl 
vinylsulfones (Figure 9) in which they introduced extensive diversity at the R1 position. 
Subsequently, they also varied the R2 position while keeping either morpholine or N-methyl 
piperazine group intact [116]. Docking studies with most active and selective inhibitor (Entry 15, 
F gure 8. B nding ode of Boc-(S)-Leu-(S)- zy-(S,S)- zi( Bn)2 n cathepsin L active site, as predicted
by ocking st ie ( icik et al., he ed h 2006, 1, 1021–1028).
3.6. Peptidyl Aryl Vinylsulfones
nother pro ising scaffold that acts as a ichael acceptor and hijacks the catalytic residue of
cysteine cathepsins is peptidyl aryl vinylsulfones. This scaffold was first introduced by Palmer et
al. as an irreversible inhibitor of cysteine cathepsins [134]. Subsequently, they extended their study
by performing an SAR analysis of this class of inhibitors which showed pan-cathepsin inhibition
with occasional selectivity towards cathepsin S for certain scaffolds [135]. However, in a separate
study by Mendieta et al., the authors developed a structurally novel library of twenty peptidyl 3-aryl
vinylsulfones (Figure 9) in which they introduced extensive diversity at the R1 position. Subsequently,
they also varied the R2 position while keeping either morpholine or N- ethyl piperazine group
intact [116]. Docking studies with most active and selective inhibitor (Entry 15, Table 2) of this class
revealed that the inhibitor extends from S2 to S2′ sites of cathepsin L and the β-vinylsulfone moiety
resides in a close proximity of Cys-25 residue thereby favoring the formation of Mich el adduct. The
authors postulate that considering the efficacy of peptidyl aryl vinyl sulfones, strong anti-cancer
candidates could be harnessed by cultivating this scaffold.
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3.7. Peptidyl Aryl Vinylsulfonate 
One other very potent class of inhibitors that also includes a Michael acceptor is peptidyl aryl 
vinylsulfonate esters, a superior Michael acceptor than vinyl sulfone. They served as potent inhibitors 
of cruzain—a parasitic cysteine protease from T. cruzi that is homologous to cathepsin L [136,137]. 
This scaffold was explored by Dana et al., who determined the superiority of aryl vinylsulfonate ester 
over aryl vinylsulfone and aryl vinylsulfonamide counterparts towards cathepsin L inhibition [117]. 
Thus, they synthesized and screened the efficacy of a library of aryl vinylsulfonate ester compounds 
against cathepsin L; 4-bromo phenyl vinylsulfonate was found to be the champion ligand presumably 
due to favorable interactions between the 4-bromo phenyl moiety with the prime site residues of 
cathepsin L. They further designed a hybrid inhibitor, KD-1, (Entry 16, Table 2) by strategically 
appending the 4-bromophenyl vinylsulfonate moiety as electrophilic warhead to a modestly potent 
reversible cathepsin L inhibitor [113]; this design was based on the hypothesis that the developed 
compound will target both the prime site and the non-prime site residues for interaction. KD-1 indeed 
exhibited almost a diffusion-controlled inactivation kinetics while maintaining an excellent 
selectivity profile toward cathepsin L (Figure 10). Furthermore, KD-1 was cell-permeable and 
inhibited the intracellular activity of cathepsin L in human MDA-MB-231 breast cancer cell lines. KD-
1 also enhanced the integrity of cell–cell junctions by effectively attenuating the migratory potential 
of the cells, as demonstrated by the scratch assay. The authors anticipated that this class of inhibitors 
may find extensive usage in deciphering context-specific cathepsin L biology. 
 
Figure 10. 4-bromophenylvinylsulfonate moiety was tethered to a known reversible inhibitor of only 
modest potency to achieve a highly potent and selective irreversible peptidyl cathepsin L-selective 
inhibitor, KD-1; this inhibitor likely binds to both prime- and non-prime sites of the enzyme. 
e eral structure of the libra y of pe tidyl aryl vinylsu fones where substituents (R1 and
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3.7. Peptidyl Aryl Vinylsulfonate
One other very potent class of inhibitors that also includes a Michael acceptor is peptidyl aryl
vinylsulfonate esters, a superior Michael acceptor than vinyl sulfone. They served as potent inhibitors
of cruzain—a parasitic cysteine protease from T. cruzi that is homologous to cathepsin L [136,137]. This
scaffold was explored by Dana et al., who determined the superiority of aryl vinylsulfonate ester over
aryl vinylsulfone and aryl vinylsulfonamide counterparts towards cathepsin L inhibition [117]. Thus,
they synthesized and screened the efficacy of a library of aryl vinylsulfonate ester compounds against
cathepsin L; 4-bromo phenyl vinylsulfonate was found to be the champion ligand presumably due to
favorable interactions between the 4-bromo phenyl moiety with the prime site residues of cathepsin
L. They further designed a hybrid inhibitor, KD-1, (Entry 16, Table 2) by strategically appending
the 4-bromophenyl vinylsulfonate moiety as electrophilic warhead to a modestly potent reversible
cathepsin L inhibitor [113]; this design was based on the hypothesis that the developed compound will
target both the prime site and the non-prime site residues for interaction. KD-1 indeed exhibited almost
a diffusion-controlled inactivation kinetics while maintaining an excellent selectivity profile toward
cathepsin L (Figure 10). Furthermore, KD-1 was cell-permeable and inhibited the intracellular activity
of cathepsin L in human MDA-MB-231 breast cancer cell lines. KD-1 also enhanced the integrity of
cell–cell junctions by effectively attenuating the migratory potential of the cells, as demonstrated by
the scratch assay. The authors anticipated that this class of inhibitors may find extensive usage in
deciphering context-specific cathepsin L biology.
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3.8. Gallinamide A Analogs
Recently, another interesting discovery that provided a wealth of information on cathepsin
L-inhibitor interactions came from marine cyanobacterial extracts. Miller et al. first reported
gallinamide A as potent irreversible inhibitor of cathepsin L with an IC50 value of 5 nM and a 28-
Molecules 2020, 25, 698 17 of 41
to 320-fold greater selectivity over cathepsin V and B, respectively [138]. They further performed
molecular docking and molecular dynamics simulations and learned that the peptidyl backbone of the
inhibitor spans the active site whereas the side chains engage in favorable interactions with different
active site pockets, placing the Michael acceptor enamide in close proximity to the catalytic Cys residue.
In a follow-up study, Boudreau et al. performed molecular docking studies to predict the potential
modifications of a gallinamide A scaffold that would harness favorable enzyme–inhibitor interactions
and enable the development of compounds with improved inhibitory efficacy [118]. They synthesized
a panel of compounds by retaining gallinamide A and only varying the amino acids at P1, P1′, and
P2′ positions. (Figure 11). This led to the discovery of the most potent analog of this series (Entry
17, Table 2) with sub-nanomolar IC50 value (94 pM) and fast time dependent inactivation kinetics,
suggesting an improved binding and reactivity of the inhibitor with the enzyme active site. The
authors found that this class of compounds effectively inactivated cruzain, a homologous cysteine
protease from T. cruzi, using cell-based assay. Gallinamide A and its analogs thus provide a remarkable
inhibitory scaffold that could potentially be harnessed to build selective enzyme inhibitors for a variety
of therapeutic applications.
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3.9. Peptidyl Aldehydes 
One classical inhibitor that has been used over a long period of time to dissect cysteine proteinase 
activity is Leupeptin, a microbial product. Leupeptin is a peptidyl aldehyde that occupies the active 
site cleft of cysteine cathepsins and forms a thiohemiacetal intermediate by trapping catalytic cysteine 
residue; this complex hydrolyzes over time, thus showing the covalent and reversible nature of the 
inhibitor (Figure 12a). Leupeptin unfortunately suffers from non-specific inhibition of both serine 
and cysteine proteinases, thus making it unfavorable for clinical usage and chemical biology 
applications. This issue was, however, addressed by Woo et al. who designed and synthesized six 
peptidyl aldehyde analogs that were more potent than Leupeptin (IC50 = 70.3 nM) and exhibited 
improved selectivity towards cathepsin L over cathepsin B and calpain II [139]. The most potent 
cathepsin L inhibitor of this series was Z-Phe-Phe-H (IC50 = 0.74 nM) (Figure 12b) that showed more 
than 90-fold selectivity over cathepsin B. Interestingly; their data demonstrated the importance of 
aromatic amino acids, such as phenylalanine and tyrosine, at the P1 position in determining the 
potency and selectivity towards cathepsin L; O-alkylation of tyrosine group diminishes the inhibitory 
efficiency as in Z-Phe-Tyr(Bu)-H (IC50: 6.96 nM). In a follow-up publication, they further tested the 
efficacy of Z-Phe-Tyr-H (IC50: 0.85 nM, 100-fold selective over cathepsin B) (Figure 12b) in vitro and 
in vivo [140]. This compound effectively inhibited parathyroid hormone-stimulated osteoclastic bone 
resorption in pit formation assays, and suppressed bone weight loss of ovariectomized mouse in a 
dose-dependent manner when administered intraperitoneally. 
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3.9. Peptidyl Aldehydes
One classical inhibitor that has been used over a long period of time to dissect cysteine proteinase
activity is Leupeptin, a microbial product. Leupeptin is a peptidyl aldehyde that occupies the active
site cleft of cysteine cathepsins and forms a thiohemiacetal intermediate by trapping catalytic cysteine
residue; this complex hydrolyzes over time, thus showing the covalent and reversible nature of the
inhibitor (Figure 12a). Leupeptin unfortunately suffers from non-specific inhibition of both serine and
cysteine proteinases, thus making it unfavorable for clinical usage and chemical biology applications.
This issue was, however, addressed by Woo et al. who designed and synthesized six peptidyl aldehyde
analogs that were more potent than Leupeptin (IC50 = 70.3 nM) and exhibited improved selectivity
towards cathepsin L over cathepsin B and calpain II [139]. The most potent cathepsin L inhibitor of
this series was Z-Phe-Phe-H (IC50 = 0.74 nM) (Figure 12b) that showed more than 90-fold selectivity
over cathepsin B. Interestingly; their data demonstrated the importance of aromatic amino acids, such
as phenylalanine and tyrosine, at the P1 position in determining the potency and selectivity towards
cathepsin L; O-alkylation of tyrosine group diminishes the inhibitory efficiency as in Z-Phe-Tyr(Bu)-H
(IC50: 6.96 nM). In a follow-up publication, they further tested the efficacy of Z-Phe-Tyr-H (IC50:
0.85 nM, 100-fold selective over cathepsin B) (Figure 12b) in vitro and in vivo [140]. This compound
effectively inhibited parathyroid hormone-stimulated osteoclastic bone resorption in pit formation
assays, and suppressed bone weight loss of ovariectomized mouse in a dose-dependent manner when
administered intraperitoneally.
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[21]. Their study revealed that the configuration of the stereogenic center (S-configuration is favored 
over R-configuration) at the P1 position, and not the steric factor, was key to the inhibitory efficacy. 
Apparently, the substituent at P1 position does not interact with S1 position residues; rather, proper 
stereogenicity allows the placement of the inhibitor in vicinity of the catalytic cysteine residue for 
interaction. S2 subsite of cathepsin L, on the other hand, preferred a hydrophobic and moderate-size 
group; α-branched alkyl chains but not the bulkier groups like phenylalanine was favorable. Further, 
the S3 subsite showed a preference for hydrophobic and bulky moieties such as 1- and 2-
naphthalenylsulfonyl substituents. Among synthesized compound, N-(1-naphthalenylsulfonyl-L-
isoleucyl-L-tryptophanal (IC50 = 1.9 nM, 789-fold selective over cathepsin B; Figure 13) attenuated the 
release of Ca2+ and hydroxyproline from bone in an in vitro bone culture system and further restricted 
bone loss in ovariectomized mice dosed orally. 
A further modification of this scaffold was reported by Lynas et al. [119] Here, authors designed 
and developed di- and tri-peptidyl α-keto-β-aldehydes, based on substrate and inhibitor specificity 
profiles of cathepsin L. The compound Z-Phe-Tyr(OBut)-COCHO (Entry 18, Table 2) turned out as 
highly potent and selective inhibitor of cathepsin L with Ki value of 0.6 nM. This molecule was further 
adapted by Shenoy et al. to assess the structural basis for cathepsin L inhibition [96]. In their study, 
the authors crystallized the glyoxal inhibitor with cathepsin L; the β-aldehyde forms a tetrahedral 
thiohemiacetal and α-keto oxygen atom is stabilized by the oxyanion hole. The Tyr(OBut) group was 
found to occupy S1 site while phenyl and carboxybenzyl groups occupied S2 and S3 sites, 
respectively. This class of inhibitors has successfully been deployed in the functional biology of 
cathepsin L. 
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cathepsin L and finds favorable interactions within the S1, S2, and S3 pockets of the enzyme. 
3.10. Azepanone-based Inhibitors 
Azepanone-based compounds were first reported as orally bioavailable and extremely potent 
inhibitors of cathepsin K, as shown by the pharmacokinetic studies in the rat [141]. Marquis et al. 
subsequently adopted the template and extended their work to acquire a selective inhibitor of 
cathepsin L with similar potency [120]. This class of inhibitors are armored with keto functional group 
Figure (a) Proposed mode of cathepsin L inact v tion by aldehyde inhibitors. ( ) Chemical structure
of inhibit rs, as discussed in text, are shown here.
In another interesting study, Yasuma et al. developed a library of compounds by varying the
amino acid substituents at P1, P2, P3 position of the inhibitor and carried out a thorough SAR
study [21]. Their study revealed that the configuration of the stereogenic center (S-configuration
is favored over R-configuration) at the P1 position, and not the steric factor, was key to the
inhibitory efficacy. Apparently, the substituent at P1 position does not interact with S1 position
residues; rather, proper stereogenicity allows the placement of the inhibitor in vicinity of the
catalytic cysteine residue for interaction. S2 subsite of cathepsin L, on the other hand, preferred
a hydrophobic and moderate-size group; α-branched alkyl chains but not the bulkier groups like
phenylalanine was favorable. Further, the S3 subsite showed a preference for hydrophobic and
bulky moieties such as 1- and 2-naphthalenylsulfonyl substituents. Among synthesized compound,
N-(1-naphthalenylsulfonyl-l-isoleucyl-l-tryptophanal (IC50 = 1.9 nM, 789-fold selective over cathepsin
B; Figure 13) attenuated the release of Ca2+ and hydroxyproline from bone in an in vitro bone culture
system and further restricted bone loss in ovariectomized mice dosed orally.
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3.10. Azepanone-based Inhibitors 
Azepanone-based compounds were first reported as orally bioavailable and extremely potent 
inhibitors of cathepsin K, as shown by the pharmacokinetic studies in the rat [141]. Marquis et al. 
subsequently adopted the template and extended their work to acquire a selective inhibitor of 
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A further modification of this scaffold was reported by Lynas et al. [119] Here, authors designed
and developed di- and tri-peptidyl α-keto-β-aldehydes, based on substrate and inhibitor specificity
profiles of cathepsin L. The compound Z-Phe-Tyr(OBut)-COCHO (Entry 18, Table 2) turned out as
highly potent and selective inhibitor of cathepsin L with Ki value of 0.6 nM. This molecule was further
adapted by Shenoy et al. to assess the structural basis for cathepsin L inhibition [96]. In their study,
the authors crystallized the glyoxal inhibitor with cathepsin L; the β-aldehyde forms a tetrahedral
thiohemiacetal and α-keto oxygen atom is stabilized by the oxyanion hole. The Tyr(OBut) group was
found to occupy S1 site while phenyl and carboxybenzyl groups occupied S2 and S3 sites, respectively.
This class of inhibitors has successfully been deployed in the functional biology of cathepsin L.
3.10. Azepanone-based Inhibitors
Azepanone-based compounds were first reported as orally bioavailable and extremely potent
inhibitors of cathepsin K, as shown by the pharmacokinetic studies in the rat [141]. Marquis et al.
subsequently adopted the template and extended their work to acquire a selective inhibitor of cathepsin
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L with similar potency [120]. This class of inhibitors are armored with keto functional group that
act as an electrophilic warhead and traps cysteine proteases by forming a transient covalent bond
with the active-site Cys residue, rendering inactivated enzyme. The authors initiated their work by
scrupulously studying the cathepsin K-inhibitor complex that revealed the influence of P2 and P3
substituents of the inhibitor in determining the efficacy and selectivity profile of the compound. Based
on these observations, they designed and synthesized a series of compound and secured a highly
potent cathepsin L inhibitor (Ki,app: 0.43 nM; Entry 19, Table 2) that exerted remarkable selectivity
over cathepsin K and fairly modest selectivity over both cathepsin B and S. Interestingly, SAR showed
that replacement of P2 leucine and P3 benzofuran of cathepsin K inhibitor with bulkier hydrophobic
aromatic groups yielded an improved potency and the selectivity towards cathepsin L (Figure 14).
Molecular docking studies further supported this observation as cathepsin K was found to have a
shallower S2 pocket than cathepsin L, thus incorporation of bulkier napthyl group at P2 position
favored cathepsin L inhibition but not cathepsin K. On the other hand, inclusion of another napthyl
group at P3 position promoted a steric clash rather than furthering the desired hydrophobic interactions
within the S3 pocket of cathepsin K, thus incurring a better selectivity profile towards cathepsin L over
cathepsin K. This template has proven to be an important tool to study cysteine cathepsins as it has
been further extended to achieve potent cathepsin S-selective inhibitor with cellular activity [142].
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3.11. Nitrile-Containing Inhibitors 
Nitrile group containing inhibitors have been widely recognized as covalent and reversible 
inhibitors of a certain class of enzymes that depend on cysteine-mediated nucleophilic attack for 
catalysis; the nitrile residue traps the sulfur and forms a thioimidate bond (Figure 15) that hydrolyzes 
over the time rendering free enzyme. Odanacatib is one of the prime examples of this class of 
compounds that has been evaluated as a clinical agent, although with limited success [143,144]. 
Because of nitrile’s tunable target engagement nature, this scaffold has been adapted to target other 
relevant enzymes, including cathepsin. Hardegger et al. utilized nitrile warhead and examined the 
effect of halogen bonding in protein–ligand interactions [121]. They developed a series of compounds 
and performed a thorough SAR analysis in which the nitrile electrophile faced towards S1 site and 
trapped the catalytic cysteine. In the developed analogs, the substituents that occupied the S3 site 
were systematically varied by strategically altering the substituents at the para-position of the phenyl 
group (Figure 16). The authors observed an improvement in inhibition profile with the placement of 
halogen at the para-position of phenyl ring which followed a trend Cl < Br < I (Entry 20, Table 2), with 
the F substituent being an outlier. Further analysis of the enzyme-inhibitor co-crystal structures 
revealed that halogen at the para position of the phenyl ring suitably interacted with Gly61 at the S3 
site; fluorine analog pointed away to avoid the electronic repulsion from the oxygen lone pairs of 
Gly61. The authors have also performed computational analysis which taken together with the crystal 
.
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3.11. Nitrile-Containing Inhibitors
Nitrile group containing inhibitors have been widely recognized as covalent and reversible
inhibitors of a certain class of enzymes that depend on cysteine-mediated nucleophilic attack for
catalysis; the nitrile residue traps the sulfur and forms a thioimidate bond (Figure 15) that hydrolyzes
over the time rendering free enzyme. Odanacatib is one of the prime examples of this class of
compounds that has been evaluated as a clinical agent, although with limited success [143,144].
Because of nitrile’s tunable target engagement nature, this scaffold has been adapted to target other
relevant enzymes, including cathepsin. Hardegger et al. utilized nitrile warhead and examined the
effect of halogen bonding in protein–ligand interactions [121]. They developed a series of compounds
and performed a thorough SAR analysis in which the nitrile electrophile faced towards S1 site and
trapped the catalytic cysteine. In the developed analogs, the substituents that occupied the S3 site
were systematically varied by strategically altering the substituents at the para-position of the phenyl
group (Figure 16). The authors observed an improvement in inhibition profile with the placement
of halogen at the para-position of phenyl ring which followed a trend Cl < Br < I (Entry 20, Table 2),
with the F substituent being an outlier. Further analysis of the enzyme-inhibitor co-crystal structures
revealed that halogen at the para position of the phenyl ring suitably interacted with Gly61 at the
S3 site; fluorine analog pointed away to avoid the electronic repulsion from the oxygen lone pairs
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of Gly61. The authors have also performed computational analysis which taken together with the
crystal data suggests O· X-C angle and the distance between the interacting atoms primarily influenced
the protein-ligand interaction. This work provides an important roadmap for developing improved
chemical biology tools where a halogen-protein interaction has successfully been utilized [97].
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To examine what effect amide···heteroarene π-stacking interactions may have on chalcogen 
bonding in the S3 pocket of cathepsin L, Giroud et al. utilized triazine-nitrile scaffold [145]. The 
authors synthesized a diverse set of triazine-nitrile compounds with a diversified heteroarenes 
targeting S3 pocket; the S1 and S2 substituents were kept constant. Among the developed compound 
library, 2-benzothienyl analog (Entry 21, Table 2) exhibited maximum inhibitory potential; 2-
benzofuranyl, 2-benzothiazolyl, and 2-imidazopyridinyl, which are of similar geometry, also 
followed a similar inhibitory pattern (Figure 17). Molecular modelling based on co-crystal structures 
showed favorable chalcogen interaction to the backbone carbonyl of Asn66 (d(S···O = CAsn66) = 3.5 
Å and the angle α(OAsn66···S-C) = 158°) at the S3 pocket; this was further supported by a 
conformational strain analysis, as chalcogen–enzyme interactions compensated for higher torsional 
strain in the S-containing ligands when compared to the benzofuranyl and imidazopyridinyl ligands. 
Their study demonstrated the importance of both intermolecular interactions and conformational 
strain in assessing the effect of heterobicyclic ligands at the S3 pocket that could be potentially be 
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interaction by targeting S3 pocket of cathepsin L enzyme.
To exa ine hat effect a ide···heteroarene π-stacking interactions ay have on chalcogen
bonding in the S3 pocket of cathepsin L, Giroud et al. utilized triazine-nitrile scaffold [145]. The authors
synthesized a diverse set of triazine-nitrile compounds with a diversified heteroarenes targeting S3
pocket; the S1 and S2 substituents were kept constant. Among the developed compound library,
2-benzothienyl analog (Entry 21, Table 2) exhibited maximum inhibitory potential; 2-benzofuranyl,
2-benzothiazolyl, and 2-imidazopyridinyl, which are of similar geometry, also followed a similar
inhibitory pattern (Figure 17). Molecular modelling based on co-crystal structures showed favorable
chalcogen interaction to the backbone carbonyl of Asn66 (d(S···O = CAsn66) = 3.5 Å and the angle
α(OAsn66···S-C) = 158◦) at the S3 pocket; this was further supported by a conformational strain
analysis, as chalcogen–enzyme interactions compensated for higher torsional strain in the S-containing
ligands when compared to the benzofuranyl and imidazopyridinyl ligands. Their study demonstrated
the importance of both intermolecular interactions and conformational strain in assessing the effect
of heterobicyclic ligands at the S3 pocket that could be potentially be utilized to develop cathepsin L
selective inhibitors.
In a subsequent study, Kuhn et al. systematically compared the effectiveness of four different
approaches: (a) selection by a medicinal chemist (b) manual modeling (c) docking followed by manual
filtering, and (d) free energy calculations (FEP). This systematic protocol enabled them to prioritize
building blocks for effective targeting of cathepsin L enzyme [123]. The authors developed a series of
36 analogs by varying only S2 substituents and keeping S1 and S3 fixed (Figure 18). After analyzing the
affinity by enzyme kinetics, they found that the FEP method was superior over other well-established
methodologies; this method not only predicted the most relevant ligands but also identified the
topological requirements of the substituents for a more effective engagement in the S2 pocket. Among
the developed compounds, cyclopentylmethyl substituent in the S2 pocket (Entry 22, Table 2) incurred
the most favorable interaction as it optimally filled the front part of the pocket. This strategy certainly
provided an edge over other conventional methodologies in predicting the optimal ligands for the S2
Molecules 2020, 25, 698 21 of 41
pocket targeting. These findings could benefit the ongoing effort of achieving a suitable therapeutic
candidate for cathepsin L enzyme.
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3.12. Thiosemicarbazone
The thiosemicarbazone moiety was first recognized as a relevant covalent and reversible warhead
of cathepsin L homologous enzyme cruzain, a protease from T. Cruzi. The mechanism of inactivaction
involves the formation of a transient covalent bond with the catalytic Cys residue (Figure 19) [148].
In an interesting study, Kishore Kumar et al. first utilized this idea and synthesized a small library of
compounds in which the most active class of inhibitors were comprised of one meta-bromo substituted
aryl ring along with another one with optimally substituted functionalities [127]. The inhibitor places
itself in the active site cleft of cathepsin L where meta-bromo substituted aryl ring occupies the S2 site
and thiosemicarbazone motif lies near the active site cysteine.
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However, when the motif was extended to capture S1′ site interaction by placing the aryl/alkyl
group at the terminal nitrogen of thiosemicarbazone, the inhibitory potency was completely diminished.
Overall, this class of inhibitors showed a good selectivity over cathepsin B and exhibited low cytotoxicity
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when tested on human cancer cell lines. In follow up studies, Kishore et al. and Parker et al. further
expanded the scope of thiosemicarbazone scaffold and developed diversely functionalized analogs
that exhibited an enhanced inhibitory potency and promising cellular activities while still retaining
the selectivity over cathepsin B [125,126]. In their latest study, Parker et al. strategically transformed
an active inhibitor with limited aqueous solubility into a water-soluble prodrug (Entry 23, Table 2),
by phosphorylation of phenolic hydroxy group; this group was readily hydrolyzable by alkaline
phosphatases, rendering the active pharmacophore [124]. The phosphate prodrug exhibited a
remarkable 600-fold increase in solubility over the parent drug and did not disintegrate in aqueous
solution, even after prolonged exposure at the physiological temperature. Furthermore, this compound
did not show any significant cytotoxicity on normal primary HUVECs cells in comparison to other
FDA-approved cytotoxic drugs, Doxorubicin and Paclitaxel. This prodrug thus far has shown promise
to be a desirable clinical candidate and the authors have proposed to evaluate its in vivo efficacy in a
preclinical setup.
3.13. Propeptide Mimics
As noted earlier, cathepsin L, like other cysteine cathepsins, contains an inhibitory propeptide
domain that spans the active site of the enzyme in the inverse direction to the regular substrate binding
mode. Chowdhury et al., in their seminal study, exploited this concept by examining the effect of a
series of synthesized tripeptidyl compounds that mimicked cathepsin L inhibitory propeptide [95].
Importantly, the developed tripeptidyl motifs also exhibited nanomolar potency; however, a moderate
truncation of the full-length propeptide drastically lost all activities [47]. Notably, while the full-length
propeptide showed only 2-fold selectivity over cathepsin K, the most potent analog of this series (Entry
24, Table 2) demonstrated a far-improved selectivity (310-fold). The authors further investigated the
binding mode of this class of inhibitors by means of co-crystal structure and molecular modeling.
This revealed that (a) arginine residue of the inhibitor occupied the S1 pocket, (b) phenyl alanine
residue found favorable hydrophobic interactions within the S2 pocket, (c) 2-phenylethyl group pointed
toward S3 pocket, (d) the methionine residue showed optimal interaction within S1′ pocket, and (e)
the biphenyl acetyl group extended to the S3′ pocket for favorable interactions [95,128]. This class
of inhibitors has shown resistance to enzyme-dependent hydrolysis and demonstrates the reversible
mode of enzyme inactivation. Overall, this inhibitor class provides a wealth of information on inhibitor
binding to cathepsin L and provides a general template for the development of therapeutic candidates
for other relevant enzymes as well.
3.14. Thiocarbazate, Oxocarbazate and Azapeptides
In an effort to discover small molecule inhibitors of cathepsin L, Myers et al. performed high
throughput screening (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR);
they identified 2,5-disubstituted oxadiazoles (Figure 20a) as potent hit compounds [129]. Surprisingly,
upon synthesis and purification of the putative inhibitory lead compounds, a complete loss of activity
was observed. The authors then investigated the compounds’ integrity from NIH MLSMR library
by LC-MS; this showed the presence of additional impurities. To trace back the active impurity,
the authors hypothesized the presence of impurities resulting from an acid-catalyzed ring-opening
reaction of thiocarbazate. The resulting azapeptides was likely the active pharmacophore that inhibited
enzyme via acylation of active site Cys; this was validated by synthesis of azapeptides and performing
the enzyme assay [149]. The (S)-stereoisomer of newly synthesized compound (Entry 25, Table 2;
Figure 20b) indeed attenuated the activity of cathepsin L with an IC50 value of 56 nM. In follow up
studies, the authors further developed a series of compounds with structural diversity and performed
a computational analysis to recognize the basis of potent enzyme inhibition [130,150] One of the
thiocarbazate analogs developed this way (Figure 20c) showed improved potency over the parent
compound. Molecular modeling studies performed with parent compound (Entry 25, Table 2) in
complex with papain indicated that indole motif preferably bound to S2 subsite, -NHBoc group engaged
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in favorable hydrophobic interactions within the S3 subsite and 2-ethylphenyl anilide extended to S1′
pocket. To further probe the importance of thiocarbazate moiety, the authors synthesized compound
containing oxocarbazate (Entry 26, Table 2) and azapeptide (Entry 27, Table 2) motifs. The oxocarbazate
showed a fairly improved IC50 value (7 nM) towards cathepsin L, whereas the azapeptide was at
best only a modest inhibitor (IC50 = 3 µM). Consistently, the binding mode of oxocarbazate exerted
similarity to that of thiocarbazate when investigated by molecular modeling studies [150].
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In a separate study, Shah et al. carried out a thorough enzymatic analysis of the champion
thiocarbazate compo nd (Entry 25, Table 2) that showed a time-dependent improvement in the
inhibition profile; the IC50 value went down to 1 nM when preincubated with cathepsin L for 4 h [131].
LC-MS a d kinetic analysis of enzyme-inhibitor complex (inhibition rate constants: kon = 24,000
M−1s−1 and koff = 2.2 × 10−5 s−1, and binding constant: Ki = 0.89 nM) demonstrated a slow-binding
kinetics and reversibility of inhibition. The selectivity over other members of the enzyme family was
modest. Interestingly, the c mpound inhibited propagation of malaria parasite Plas odium falciparum
[IC50 = 15.4 µM], and Leishma ia major [IC50 = 12.5 µM], and did not exhibit any significant toxicity
against human aortic e dothelial cells and zebrafish. Although thiocarbazate motif showed promise as
an inhibit ry scaffold, the lack of reasonable stability (it decomposes even in DMSO) and only modest
i i it r activity in cell-based assays probably ceased any further development of the scaffold [129].
The authors also extended their studies to evaluate the potential of oxocarbazate inhibitor that showed
an improved IC50 value of 0.4 nM pon 4 h preincubation with the enzyme. Like as in the case
of thiocarbazate, th y performed an enzyme ki etic analysis of the enzym -i hibitor complex and
obtained the following parameters: inhibition rate constants: kon = 153,000 M−1s−1 and koff = 4.4 ×
10−5 s−1, an binding co stant: Ki = 0.29 nM [132]. The i hibitor blocked SARS-CoV (IC50 = 273 ±
49 nM) Ebola virus (IC50 = 193 ± 39 nM) entry into the human embryonic kidney (HEK) 293T
cells, a process that utilizes cathepsin L-mediated pr teolysis for host cell infection. The oxocarbazate,
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when treated with HEK 293T lysate in the presence of DCG-04, an activity-based cysteine cathepsin
probe, showed reduced cathepsin L labeling when assessed by a Western-blot analysis; this further
corroborated the results obtained from the virus pseudotype infection assay. Overall, oxocarbazate
inhibitor not only provided a promising template for further exploitation but also rendered a new
direction for intervening SARS and Ebola virus infections.
4. Molecular Probes
Ubiquitous expression of human cathepsin L in most human tissues possesses a significant
challenge in targeting this enzyme for therapeutic development. This problem is further exacerbated
with recent findings that alternative spliced isoforms could exist at distinct cellular locations (e.g.,
nucleus, cytosol, and ECM space) [37,38,151]. While several unique functional roles of cathepsin L are
known, it has also been reported that some of its function can also be accomplished by other members
of the cathepsin family (i.e., functional redundancy); for example, both cathepsin L and B can mediate
a mutually compensatory role in the inflammatory response signaling pathways [152]. In this regard,
accurate function of cathepsin L must be first determined in different cell types individually before
considering significant investment in drug development. Since the function of an enzyme, such as
cathepsin L, depends primarily on its activity profile and given that the activity profiles of differentially
processed cathepsin L isoforms may be very different, probes capable of reporting accurate activity
status in different cell types (and cellular location) are anticipated to advance our understanding if
cathepsin L biology. Over the years, the concept of Activity-Based Probes (ABPs) has emerged as
a valuable chemical biology tool for monitoring the enzyme activity (not just the expression profile
alone) in cells at the proteome levels [153–156].
In most cases, existing covalent inhibitors containing a recognition motif are adopted and
transformed to ABPs by conjugating optimal detection modalities; these include fluorescent probes,
affinity labels, radiotracer, and many others (Figure 21). Indeed, the use of ABPs has rather established
cathepsins as key diagnostic marker for various disease conditions, and have even enabled optical
surgical navigation, leading to an improved surgical precision [157,158]. In the following sections, we
discussed cathepsin L-selective molecular probes that have been developed and utilized for monitoring
its activity. A thorough overview of cathepsin probe development for imaging purpose could be found
elsewhere [10,159–161].
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4.1. Radio-Labelled
Radio-labeled inhibitors have long been used as a primary mode for detecting active cysteine
proteases both in vitro and in vivo. Docherty et al. first used a chloromethyl inhibitor containing
radioactive iodine, 125I-Tyr-Ala-Lys-ArgCH2Cl, and detected cathepsin B in crude granule fraction
of islet cells [162]. In their follow up study, they also presumably identified cathepsin L in insulin
secretory granule using the same radio-isotopically labeled inhibitor [163]. The mechanism of
detection involves covalent modification of the target protein that shows up as a distinct band upon
performing autoradiography. This chloromethyl containing inhibitor turned out to be non-selective
due to its reactivity towards trypsin, a serine protease. This was followed by the discovery of a
radioactive-peptidyldiazomethane compound (Entry P1, Table 3), a selective cysteine proteinase
inhibitor [164]. Mason et al. adopted the peptidyldiazomethane scaffold, which potently inhibited both
cathepsin L and B. This scaffold showed improved inhibition profile upon iodination, as demonstrated
by Crawford et al. [103] This inhibitory agent was then transformed to a radio-labeled probe via
incorporation of 125I [164]. The developed probe was utilized to detect both cathepsin L and B in
Kirsten-virus-transformed KNIH 3T3 cells. The incubation of cellular extracts with P1 followed by gel
electrophoresis showed the presence of two protein bands at 30 and 23 kDa, showing two active forms
of cathepsin L. Active cathepsin B was also detected at around 33–35 kDa. Interestingly, pulse-chase
experiments with [35S]methionine-labeled proteins only detected two separate bands at 36 kDa and
39 kDa, which correspond to the intracellular inactive precursors of cathepsin L and B respectively.
This indicated that the inactive precursor proteins did not react with P1, demonstrating its unique
ability to quantify only active protein. Further, P1 was utilized to probe active cathepsin L and B in
different human tissues as well as in lysosomes and whole cells [165,166]. In a follow-up study, Xing et
al. developed Fmoc-[I2]Tyr-Ala-CHN2 (Entry P2, Table 3) that selectively detected cathepsin L and
B over cathepsin S, exhibiting a faster rate of inactivation towards cathepsin L [167]. The developed
compound successfully probed the amount of active cathepsin L and B in different cell-lines; two
unknown proteins also got labeled in certain cases. Overall, these probes enabled the detection of
active cathepsin enzymes with their cellular location, thereby advancing the knowledge of cathepsin
L biology.
Table 3. Reported probes of cathepsin L, their detection module, efficacy, and utilities.
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4.2. Affinity-Based 
Gelhaus et al. first developed biotinylated aziridine-2,3-dicarboxylate and demonstrated its anti-
plasmodial activity using cell-based studies [168]. Since, the biotinylated compound inhibited 
plasmodial protease falcipain and cathepsin L, authors suggested that this scaffold could be utilized 
for the development of cell-permeable, non-radioactive reagents that selectively labels enzymes 
involved in parasite pathogenicity. Later on, Vicik et al. adopted this motif (Entry P3, Table 3) and 
developed an affinity label to probe cathepsin L activity [133]. The aziridine analog irreversibly 
inactivates the enzyme via covalent modification, as discussed previously. The conjugated biotin 
moiety is utilized for affinity pull down and target identification. When (S,S) isomer of the 
biotinylated probe was incubated with cathepsin L and subjected to gel electrophoresis, electro-
transferred to a membrane, and exposed to streptavidin-alkaline phosphatase conjugate, a strong 
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4.2. Affinity-Based
Gelhaus et al. first developed biotinylated aziridine-2,3-dicarboxylate and demonstrated its
anti-plasmodial activity using cell-based studies [168]. Since, t e biotinylated compound inhibited
plasmodial pr tease falcipain and cathepsin L, authors suggested that this scaffold could be utilized for
the development of cell-per eable, no -ra oactive reagents that selectiv ly labels enzymes involved
in parasite pathogenic ty. Later on, Vicik et al. adopt d this motif (Entry P3, Table 3) and developed
an affinity label to probe cathepsin L activity [133]. The aziridine analog irrev r ibly inactivates the
enzyme via covalent modificat on, as discussed previously. The conjugated biotin moie y is utilized for
affinity pull down and target i entification. When (S,S) isomer of the biotinylated probe was incubated
with cathepsin L and subjected to gel electrophoresis, electro-transferr d t a membrane, and exposed
to streptavidin-alkaline phosphatase conjugate, a strong labeling of the enzyme-inhibitor complex
was observed. However, when the enzyme was treated with E-64, an active site-directed competitive
and irreversible cathepsin inhibitor, prior to incubation with P3, the labeling was diminished, clearly
demonstrating that P3 competes for the active site of cathepsin L. In line with this observation, a
desthiobiotinylated analog also exhibited the same trend but with reduced labeling due to its weaker
binding affinity to streptavidin. Although P3 has a modest binding affinity (Ki = 1.4 µM) to cathepsin
L, it exerted a 36-fold selectivity over cathepsin B. Certainly, the affinity labeling technique not only
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served as an ABP for cathepsin L but also provides a premise for developing aziridine-based chemical
tools for functional proteomics.
4.3. Photoaffinity-Based
Although covalent modifiers of proteins have been vastly exploited as chemical tools for target
identification and functional proteomics, photoaffinity probes offer unique mode of action. They bind
proteins non-covalently (affinity based solely on non-covalent interactions) first and form a non-selective
covalent bond with the closest amino acid residue only upon irradiation. Torkar et al. took advantage
of this technique and developed the first photoaffinity-based probe (Entry P3, Table 3) to detect
active cathepsin L selectively over other members of the family [170]. The photoaffinity-based
probe was designed based on existing peptidyl acetyloxymethyl ketone (AOMK), a known covalent
modifier of cysteine proteases. During the design, the AOMK group at the C-terminus was
replaced by a short di(ethylene glycol) moiety that increased the aqueous solubility and altered
the character of the inhibitor from irreversible to a reversible one. The probe was comprised of a
lysine residue that was strategically placed to append fluorescent cyanine-3 (Cy3) group for detection.
A photoactivatable benzoylphenylalanine amino acid was placed to accommodate the S2 pocket of
cathepsin L. The developed probe detected recombinant cathepsin L upon incubation and subsequent
irradiation for 40 min at 365 nm as demonstrated by SDS-PAGE. The protein band became invisible
when enzyme was incubated with known cathepsin L inhibitors, E-64 and GB111-NH2, respectively,
prior to the probe treatment [175,176]. The probe also showed preferential selectivity towards cathepsin
L when compared to other two fluorescent-based probes. The probe P3 exhibited a remarkable
selectivity for cathepsin L over all other cathepsins in light-mediated labeling experiments with
recombinant proteins. The relative labeling percentages (cathepsin B and K: 4%; cathepsin S: 1%) were
insignificant, except for cathepsin V (27%), the closest homolog of cathepsin L, relative to cathepsin
L. Interestingly, U87-MG glioma cell extracts did not present any cathepsin L for detection with the
P3 probe. However, when the same cell extracts were treated with recombinant cathepsin L added
externally and subjected to a labeling experiment, the probe selectively detected the desired protein
in complex proteome. The mechanism of protein labeling by P3 was attributed to putative bond
formation between benzophenone and non-conserved Met161 at the S2 site of cathepsin L. Although
the developed probe lacks cell-penetrability, the authors envisioned that the technique might have
diagnostic and prognostic value where cathepsin L overexpression is high, such as in malignant tissues.
4.4. Fluorescence-Based
4.4.1. Two-Photon Based
Although several fluorescent-based molecular probes have been reported for cysteine cathepsins,
the superiority of two-photon-based over one-photon based imaging technique inspired Na et al. to
develop probes with a better cellular imaging profile [171]. Notably, the two-photon fluorescence
imaging technique provides increased tissue penetration depth with reduced photobleaching, and a
lower tissue autofluorescence. The authors first fabricated a microarray with 105 different peptidyl
aldehydes and screened against GFP-labeled cathepsin L enzyme; this led to the identification
of two inhibitory hits that potently inactivated enzyme with IC50 values of 14.5 and 20.8 nM.
The lead inhibitors were further structurally modified to include (a) a two-photon dye, DL-1 (a
4,6-bis(4-hydroxystyryl)pyrimidine derivative), at P1 position, and (b) Disperse Red 1 dye, a fluorescence
quencher, in the place of aldehyde moiety. The resulting imaging probes (Entry P5 in Table 3 is one
of such examples) showed a time-dependent increase in fluorescence signals when treated with
HepG2 cell lysates, a mammalian liver cancer cell-line known to overexpresses cysteine cathepsins.
Enhanced fluorescence signal is due to the release of the quencher upon successful proteolytic cleavage.
Furthermore, to assess the suitability of P5 as imaging agents for live cells, HepG2 cells were incubated
with the probe and subjected to a live-cell imaging analysis. There were strong fluorescence signals
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from endolysomal compartments that disappeared completely when cells were pretreated with E-64,
validating the target specificity of the probe. As the probe was developed using cathepsin L as a
model enzyme, it likely will lack specificity and perhaps interact with other members of the family.
Still, however, this motif could potentially be utilized to develop selective ABPs targeting respective
cathepsins and assess their activities in a tissue environment, as proposed by the authors.
4.4.2. One-Photon Based
Activity-based probes with a single photon fluorescent tag have been successfully utilized for
the functional analysis of target proteins both in vitro and in vivo. Poreba et al., in their pursuit of
developing cathepsin L selective imaging agent, took advantage of this technology [172]. They realized
the importance of developing selective cathepsin L substrate that will bind to the active site of the
enzyme over other homologous proteins. To do so, they employed Hybrid Combinatorial Substrate
Library (HyCoSuL) technology that provides information on optimal chemical space inside the
enzyme active sites by strategically scanning diverse peptide library containing both natural and
unnatural amino acids. This led to the acquisition of a panel of compounds with desired properties.
The potent hits discovered by HyCoSuL technology were further optimized to gain selectivity over
other cathepsins while identifying the most efficient substrate based on Michaelis Menten parameters.
Unfortunately, when the chosen peptide substrate transformed to an activity-based probe by appending
an acyloxymethylketone warhead and a biotin tag, it showed cross-reactivity with cathepsin B. Despite
biotinylated probe’s somewhat compromised selectivity, the authors still assessed its activity-based
labeling profile in HEK293T cells; as expected, cathepsin L labeling was primarily observed with minor
amounts of cathepsin B. Further optimization by swapping the biotin and Arg with cyanine-5 and
Cys(Bzl) (Entry P6, Table 3) groups was carried out next. The newly developed fluorescent ABP, P6,
showed an enhanced selectivity (in comparison to pan-cathepsin probes) against a panel of other
recombinant cathepsins (cathepsin V, B, S, and K), as well as cellular extracts derived from HEK293T and
MDA-MB-231 cells. The developed probe served as an effective imaging agent for cellular cathepsin
L activity in human MDA-MB-231 breast cancer cells when incubated for 8 h. The selectivity of
the probe started to recede with longer incubation time. The importance of optimizing the probe
concentration and time-course of the reaction was evident from these experiments. Interestingly, P6
only detected active cathepsin L and not procathepsin L; this certainly signifies the effectiveness of
the developed probes as an activity-based probe. The authors further examined the colocalization
of the probe with both cathepsin L and B in MDA-MB-231 cells by treating the cells with respective
cathepsin antibodies and performing a quantitative pixel analysis from a set of fluorescence microscopy
images. This supported the previous observation as the highest weighted colocalization coefficient
was obtained for cathepsin L and not for cathepsin B. The developed compound certainly harbors
the key traits of an effective activity-based probe, as the authors duly envisioned its significance in
deciphering cathepsin L biology in the coming years.
4.5. Clickable and Tagless
As noted above, fluorescence-based imaging probes have been successfully developed to gain
access to unknown functionalities of cathepsin enzymes. However, the bulkiness and often multiple
charges associated with the fluorophore and/or quencher structures on these probes likely render them
poorly cell-permeable and reduce their target affinity. To address this issue, Dana et al. adopted a
previously reported peptidyl vinylsulfonate inhibitor KD-1—a highly potent, selective, covalent and
irreversible inhibitor of cathepsin L discussed in Section 3.7—and tactically appended a small alkynyl
group at the para-position of the Cbz group [117]. This led to the development of a clickable and tagless
activity-based probe (catABP) of cathepsin L that retained the key desirable traits of KD-1; i.e., cell
permeability, charge profile, molecular weight, potency and selectivity profile [170]. This strategy
eliminated the requirements of including bulky and charged fluorophore/quencher moiety to the
probe. One of the inherent advantages of this approach is that the labeling can be performed in live
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cellular environment with high efficiency. After cell lysis, the labeled cathepsin L can be quantified by
performing click chemistry protocol with a fluorescent azide containing dye, resolving the protein using
gel-electrophoresis, and directly scanning the gel for fluorescence signal. As anticipated, the developed
KDP-1 probe (Entry P7, Table 3), exhibited rapid inactivation kinetics, retained selectivity for cathepsin
L, and labeled recombinant active cathepsin L in an activity-dependent manner; the heat-denatured
and E-64 treated cathepsin L showed no labeling when subjected to the identical labeling protocol.
A mass-spectrometric analysis of the enzyme-probe complex concluded that the probe was active-site
directed, and covalently modified the catalytic Cys residue for inactivation. Since the KDP-1 probe was
developed with the intention of capturing active cathepsin L in vivo and in human live cell culture, the
probe was tested for its cytotoxicity in MDA-MB-231 cells; no cytotoxicity was observed in these cells,
even at a concentration as high as 10 µM. Incubation of MDA-MB-231 cells overexpressing cathepsin L
with KDP-1 attenuated the intracellular cathepsin L activity in a dose-dependent manner; this was
demonstrated by live-cell imaging and wound healing assay. Finally, KDP-1 also interfered with
the hatching process of post-fertilized zebrafish embryos, further validating probe’s in vivo activity;
notably, cathepsin L serves as the key regulator of the hatching process [177–179]. In conclusion,
KDP-1 demonstrated many desirable attributes of a good probe and is anticipated to find extensive
applications in probing cathepsin L function in cells from diverse origins.
4.6. Mass Cytometry-Compatible Activity-Based Probes
Although fluorophores-containing molecules have been appreciated as useful imaging probes,
commonly used fluorophores often suffer from spectral overlapping that limits the number of targets
that can be analyzed concomitantly [180]. To address this issue, Poreba et al. recently developed
protease-selective lanthanide-labeled probes compatible with mass cytometry which allows subsequent
analysis by both mass and imaging mass cytometry (IMC) [171]. These metal-tagged, time of flight
activity-based probes (TOF) allowed them to determine cellular activities and location of three lysosomal
proteases. Thus, using cathepsin L, B, and legumain as the model systems, they elegantly crafted an
activity-based probe by incorporating (a) a protease-selective peptide sequence for specific enzyme
recognition, (b) the acyloxymethylketone as electrophilic warhead to trap the target enzyme, and (c)
the dodecanetetraacetic acid (DOTA) for metal chelation that is tethered to the peptide sequence via a
linker (Entry P8, Table 3). They further incorporated three different lanthanides, 159Tb, 175Lu, and Gd
(a mixture of naturally occurring six isotopes), to validate their approach and to further evaluate the
influence of isotopes on enzyme binding specificity. The newly developed probes exerted promising
selectivity toward both recombinant proteases and proteases from cancer cell lines, HCT-116 and
MDA-MB-231.The authors were able to simultaneous detect the activities of proteases in HCT-116
cells. Moreover, each of the protease-specific probes exerted a similar labelling efficiency in HCT-116
cells, regardless of their metal counterparts, which further reinforces the compatibility of this class of
probes as cytometry-labelling agents. They extended their investigation to THP-1 cells, a non-adherent
monocyte-like cell line, that expresses both cathepsin B and L but contains very low levels of legumain
enzyme. Probe treated THP-1 showed a clear labeling of both cathepsin B and L with no detectable
activity of legumain. This finding was consistent with their transcriptional data. Finally, the developed
probes not only allowed to detect the activome of cathepsin L, B, and legumain in peripheral blood
mononuclear cells (PBMC) but also enabled to categorize NK cells in two distinct populations based
on protease activome levels. This strategy, unlike many existing technologies, thus allowed the
simultaneous detection of target proteases, thereby providing a more holistic understanding of the
activome. This certainly merits the future development of TOF-based probes for multiplexed enzyme
activity detection.
5. Final Perspectives
The inhibition of cathepsin L has continue to emerge at the forefront of drug development for
several human diseases. Yet, no inhibitory agents targeting cathepsin L have advanced to clinical
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trials. While inhibitors of cathepsin B and S are currently being evaluated in clinical trials, recent
failure of Odanacatib, a cathepsin K inhibitor for osteoporosis, in late stage clinical trial has made
pharmaceutical industries wary of targeting cathepsins. The key challenge remains gaining inhibitor
selectivity with respect to the other members of cathepsins and directing them to the targeted cell types
for selective functional perturbation. With its ubiquitous expression profile, the function of cathepsin
L in individual cell types must be precisely defined first; this is especially important since several
isoforms of cathepsin L have been reported in the distinct cellular locations, and their activity and
functional profile in individual cell types still remain poorly documented. While recently developed
cathepsin inhibitors and probes have significantly advanced our understanding of cathepsin L function
in both normal and disease cells, more efforts are needed for the development of isoform-selective
reagents for further advancement; perhaps new allosteric modules on cathepsin L enzyme can be
explored and exploited for precision targeting. Fortunately, several structural coordinates for cathepsin
L enzyme forms, some with a diverse set of complexing ligands and some without, are now available
(Table 4). These could aid in the development of isoform-selective inhibitory probes that will enable
researchers to assess the context-specific needs of targeting cathepsin L in different cellular states.
In recent years, disease-associated protease activatable prodrugs have gained much recognition and
garnered breakthrough therapies in the area of antibody-drug conjugation (ADC) [181]. The majority
of the ADCs are constructed by tethering a cytotoxic drug with an antibody via a protease-sensitive
module for targeted delivery. Cathepsin B-specific module, for example, has been successfully
implemented for this role, which led to the development of FDA approved therapies; for example,
Brentuximab vedotin (Adcetris®) for CD30-positive relapsed or refractory Hodgkin′s lymphoma.
In addition, protease cleavable prodrug strategy has also inspired the development of cathepsin B
selective probe and even enabled real-time monitoring of drug release [182,183]. Interestingly, Ueki et
al. slightly maneuvered this approach to acquire a prodrug which gets serially activated by histone
deacetylase (HDAC) and cathepsin L, and subsequently delivers the cytotoxic payload, puromycin, to
cancer cells [184]. This strategy has thus enabled selective targeting of cancer cells, specifically with
high HDAC and cathepsin L activities. Taken together, these developments surely lay the foundation
for the development of future cathepsin L-based therapies. Much excitement remains as new cathepsin
L functions continue to emerge from specific cell types in the coming years.
Table 4. Reported structural studies of cathepsin L enzyme.
PDB Entry Method Resolution (Å) Reference
1CJL X-ray 2.20 [42]
1CS8 X-ray 1.80 [42]
1ICF X-ray 2.00 [42]
1MHW X-ray 1.90 [95]
2NQD X-ray 1.75 [185]
2VHS X-ray 1.50 [186]
2XU1 X-ray 1.45 [121]
2XU3 X-ray 0.90 [121]
2XU4 X-ray 1.12 [121]
2XU5 X-ray 1.60 [121]
2YJ2 X-ray 1.15 [97]
2YJ8 X-ray 1.30 [97]
2YJ9 X-ray 1.35 [97]
2YJB X-ray 1.40 [97]
2YJC X-ray 1.14 [97]
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Table 4. Cont.
PDB Entry Method Resolution (Å) Reference
3BC3 X-ray 2.20 [187]
3H89 X-ray 2.50 [128]
3H8B X-ray 1.80 [128]
3H8C X-ray 2.50 [128]
3HHA X-ray 1.27 [147]
3HWN X-ray 2.33 [147]
3IV2 X-ray 2.20 [188]
3K24 X-ray 2.50 [188]
3KSE X-ray 1.71 [189]
3OF8 X-ray 2.20 [96]
3OF9 X-ray 1.76 [96]
4AXL X-ray 1.92 [190]
4AXM X-ray 2.80 [190]
5F02 X-ray 1.43 [191]
5I4H X-ray 1.42 [192]
5MAE X-ray 1.00 [145]
5MAJ X-ray 1.00 [145]
5MQY X-ray 1.13 [123]
6EZP X-ray 1.37 [98]
6EZX X-ray 2.34 [98]
6F06 X-ray 2.02 [98]
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